A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year

S. Bastianello, C. Pozzilli, F. D'Andrea, E. Millefiorini, M. Trojano, S. Morino, C. Gasperini, A. Bozzao, M. Gallucci, C. Andreula, L. Bozzao, D. Gambi, M. Prencipe

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p <0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.

Original languageEnglish
Pages (from-to)266-270
Number of pages5
JournalCanadian Journal of Neurological Sciences
Volume21
Issue number3
Publication statusPublished - 1994

Fingerprint

Mitoxantrone
Multiple Sclerosis
Gadolinium DTPA
Magnetic Resonance Imaging
Placebos
Relapsing-Remitting Multiple Sclerosis
Therapeutics
Multicenter Studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Bastianello, S., Pozzilli, C., D'Andrea, F., Millefiorini, E., Trojano, M., Morino, S., ... Prencipe, M. (1994). A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year. Canadian Journal of Neurological Sciences, 21(3), 266-270.

A controlled trial of mitoxantrone in multiple sclerosis : Serial MRI evaluation at one year. / Bastianello, S.; Pozzilli, C.; D'Andrea, F.; Millefiorini, E.; Trojano, M.; Morino, S.; Gasperini, C.; Bozzao, A.; Gallucci, M.; Andreula, C.; Bozzao, L.; Gambi, D.; Prencipe, M.

In: Canadian Journal of Neurological Sciences, Vol. 21, No. 3, 1994, p. 266-270.

Research output: Contribution to journalArticle

Bastianello, S, Pozzilli, C, D'Andrea, F, Millefiorini, E, Trojano, M, Morino, S, Gasperini, C, Bozzao, A, Gallucci, M, Andreula, C, Bozzao, L, Gambi, D & Prencipe, M 1994, 'A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year', Canadian Journal of Neurological Sciences, vol. 21, no. 3, pp. 266-270.
Bastianello, S. ; Pozzilli, C. ; D'Andrea, F. ; Millefiorini, E. ; Trojano, M. ; Morino, S. ; Gasperini, C. ; Bozzao, A. ; Gallucci, M. ; Andreula, C. ; Bozzao, L. ; Gambi, D. ; Prencipe, M. / A controlled trial of mitoxantrone in multiple sclerosis : Serial MRI evaluation at one year. In: Canadian Journal of Neurological Sciences. 1994 ; Vol. 21, No. 3. pp. 266-270.
@article{6640d3d95b6d4b18a4a8e78d5a9f0431,
title = "A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year",
abstract = "We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p <0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.",
author = "S. Bastianello and C. Pozzilli and F. D'Andrea and E. Millefiorini and M. Trojano and S. Morino and C. Gasperini and A. Bozzao and M. Gallucci and C. Andreula and L. Bozzao and D. Gambi and M. Prencipe",
year = "1994",
language = "English",
volume = "21",
pages = "266--270",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "3",

}

TY - JOUR

T1 - A controlled trial of mitoxantrone in multiple sclerosis

T2 - Serial MRI evaluation at one year

AU - Bastianello, S.

AU - Pozzilli, C.

AU - D'Andrea, F.

AU - Millefiorini, E.

AU - Trojano, M.

AU - Morino, S.

AU - Gasperini, C.

AU - Bozzao, A.

AU - Gallucci, M.

AU - Andreula, C.

AU - Bozzao, L.

AU - Gambi, D.

AU - Prencipe, M.

PY - 1994

Y1 - 1994

N2 - We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p <0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.

AB - We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p <0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhanced MRI detected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0027968510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027968510&partnerID=8YFLogxK

M3 - Article

C2 - 8000984

AN - SCOPUS:0027968510

VL - 21

SP - 266

EP - 270

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 3

ER -